ARTICLE | Company News
Angiochem grants Xinogen Chinese rights to ANG1005
January 5, 2018 10:47 PM UTC
Angiochem Inc. (Montreal, Quebec) granted Xinogen Hong Kong Pharma Co. Ltd. exclusive, Chinese rights to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a peptide (Angiopep-2) conjugated to three paclitaxel molecules for receptor-mediated transport into the brain. Xinogen is a subsidiary of Shenogen Pharma Group Ltd. (Beijing, China).
Angiochem will receive an upfront payment and is eligible for milestones and royalties. Details were not disclosed...